UPDATE: Isis, Hybridon Enter $40M Antisense Deal | GenomeWeb

This story has been updated from a previous version.

NEW YORK, May 25 - Isis Pharmaceuticals and Hybridon said Friday they had penned several cross-licensing agreements for antisense technologies, in a deal valued at more than $40 million in cash and stock. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.